These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 17921036

  • 1. Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans.
    Knight LC, Romano JE, Bright LT, Agelan A, Kantor S, Maurer AH.
    Nucl Med Biol; 2007 Oct; 34(7):855-63. PubMed ID: 17921036
    [Abstract] [Full Text] [Related]

  • 2. Functional expression of bitistatin, a disintegrin with potential use in molecular imaging of thromboembolic disease.
    Knight LC, Romano JE.
    Protein Expr Purif; 2005 Feb; 39(2):307-19. PubMed ID: 15642483
    [Abstract] [Full Text] [Related]

  • 3. In vitro platelet binding compared with in vivo thrombus imaging using alpha(IIb)beta3-targeted radioligands.
    Knight LC, Romano JE, Maurer AH.
    Thromb Haemost; 1998 Nov; 80(5):845-51. PubMed ID: 9843182
    [Abstract] [Full Text] [Related]

  • 4. Comparison of iodine-123-disintegrins for imaging thrombi and emboli in a canine model.
    Knight LC, Maurer AH, Romano JE.
    J Nucl Med; 1996 Mar; 37(3):476-82. PubMed ID: 8772651
    [Abstract] [Full Text] [Related]

  • 5. Pre-clinical evaluation of technetium-99m platelet receptor-binding peptide.
    Lister-James J, Vallabhajosula S, Moyer BR, Pearson DA, McBride BJ, De Rosch MA, Bush LR, Machac J, Dean RT.
    J Nucl Med; 1997 Jan; 38(1):105-11. PubMed ID: 8998163
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Thrombus imaging with a technetium-99m-labeled activated platelet receptor-binding peptide.
    Lister-James J, Knight LC, Maurer AH, Bush LR, Moyer BR, Dean RT.
    J Nucl Med; 1996 May; 37(5):775-81. PubMed ID: 8965144
    [Abstract] [Full Text] [Related]

  • 8. Thrombus imaging with technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets.
    Knight LC, Radcliffe R, Maurer AH, Rodwell JD, Alvarez VL.
    J Nucl Med; 1994 Feb; 35(2):282-8. PubMed ID: 8295000
    [Abstract] [Full Text] [Related]

  • 9. New and versatile ternary ligand system for technetium radiopharmaceuticals: water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc.
    Edwards DS, Liu S, Barrett JA, Harris AR, Looby RJ, Ziegler MC, Heminway SJ, Carroll TR.
    Bioconjug Chem; 1997 Feb; 8(2):146-54. PubMed ID: 9095354
    [Abstract] [Full Text] [Related]

  • 10. Technetium-99m-labeled platelets: comparison of labeling with a new lipid-soluble Sn(II)-mercaptopyridine-N-oxide and 99mTc-HMPAO.
    Dewanjee MK, Robinson RP, Hellman RL, Ganz WI, Serafini AN, Sfakianakis GN.
    Int J Rad Appl Instrum B; 1991 Feb; 18(5):461-8. PubMed ID: 1917515
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and renal handling of 99mTc-labeled peptides.
    Trejtnar F, Laznicek M, Laznickova A, Mather SJ.
    J Nucl Med; 2000 Jan; 41(1):177-82. PubMed ID: 10647621
    [Abstract] [Full Text] [Related]

  • 12. The safety and pharmacokinetics in adult subjects of an intravenously administered 99mTc-labeled 17 amino acid peptide (CYT-379).
    Ben-Haim S, Kahn D, Weiner GJ, Madsen MT, Waxman AD, Williams CM, Clarke-Pearson DL, Coleman RE, Maguire RT.
    Nucl Med Biol; 1994 Feb; 21(2):131-42. PubMed ID: 9234275
    [Abstract] [Full Text] [Related]

  • 13. Effect of iron deficiency anemia on the biodistribution of 99mTc radiopharmaceuticals.
    Calmanovici GP, Salgueiro MJ, Janjetic MA, Leonardi NM, Boccio JR, Zubillaga MB.
    Nucl Med Biol; 2006 May; 33(4):581-4. PubMed ID: 16720252
    [Abstract] [Full Text] [Related]

  • 14. Preclinical evaluation of technetium 99m-labeled P1827DS for infection imaging and comparison with technetium 99m IL-8.
    Krause S, Rennen HJ, Boerman OC, Baumann S, Cyr JE, Manchanda R, Lister-James J, Corstens FC, Dinkelborg LM.
    Nucl Med Biol; 2007 Nov; 34(8):925-32. PubMed ID: 17998094
    [Abstract] [Full Text] [Related]

  • 15. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
    Prueksaritanont T, Gorham LM, Naue JA, Hamill TG, Askew BC, Vyas KP.
    Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
    [Abstract] [Full Text] [Related]

  • 16. Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: increased destruction of circulating platelets.
    Nash RA, Burstein SA, Storb R, Yang W, Abrams K, Appelbaum FR, Boone T, Deeg HJ, Durack LD, Schuening FG.
    Blood; 1995 Sep 01; 86(5):1765-75. PubMed ID: 7655007
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Study of the toxicological effect of mitomycin C in mice: alteration on the biodistribution of radiopharmaceuticals used for renal evaluations.
    Gomes ML, de Mattos DM, de Souza Freitas R, Bezerra RJ, Bernardo-Filho M.
    Hum Exp Toxicol; 2001 Apr 01; 20(4):193-7. PubMed ID: 11393272
    [Abstract] [Full Text] [Related]

  • 20. Preparation of 99mTc-labelled conjugates of ouabagenin and their biological evaluation in animal models.
    Debnath MC, Sarkar BR, Ganguly S, Banerjee S.
    Nucl Med Commun; 2006 Mar 01; 27(3):271-9. PubMed ID: 16479248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.